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Abstract
IL-18 has pleotropic effects on the activation of T cells during antigen presentation. We investigated the effects of human IL-
18 on the engraftment and function of human T cell subsets in xenograft mouse models. IL-18 enhanced the engraftment of
human CD8
+ effector T cells and promoted the development of xenogeneic graft versus host disease (GVHD). In marked
contrast, IL-18 had reciprocal effects on the engraftment of CD4
+CD25
+Foxp3
+ regulatory T cells (Tregs) in the xenografted
mice. Adoptive transfer experiments indicated that IL-18 prevented the suppressive effects of Tregs on the development of
xenogeneic GVHD. The IL-18 results were robust as they were observed in two different mouse strains. In addition, the
effects of IL-18 were systemic as IL-18 promoted engraftment and persistence of human effector T cells and decreased Tregs
in peripheral blood, peritoneal cavity, spleen and liver. In vitro experiments indicated that the expression of the IL-18Ra was
induced on both CD4 and CD8 effector T cells and Tregs, and that the duration of expression was less sustained on Tregs.
These preclinical data suggest that human IL-18 may have use as an adjuvant for immune reconstitution after cytotoxic
therapies, and to augment adoptive immunotherapy, donor leukocyte infusions, and vaccine strategies.
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Introduction
Initially isolated from macrophages as a potent interferon-c
(IFN-c)-inducing factor [1,2], Interleukin-18 (IL-18) is a multi-
functional cytokine affecting both innate and adaptive immune
responses [3,4]. IL-18 is produced as an inactive precursor (pro-
IL-18), which is activated by proteolytic cleavage, primarily by
caspase-1 [5,6]. Pro-IL-18 is produced by multiple cell types,
including macrophages [1], dendritic cells [7], vascular endothelial
cells [8], and intestinal epithelial cells [9].
Numerous effector functions have been attributed to IL-18.
Perhaps the best characterized of these is IL-18’s context-dependent
induction of Th1 or Th2 CD4 T cell polarization [3]. In the
presence of IL-12, IL-18 drives the Th1 polarization of activated
CD4
+Tcells.However,intheabsenceofIL-12(orinthepresenceof
IL-2 or IL-4), IL-18 promotes IgE expression and Th2 differenti-
ation. More recently, IL-18 has been demonstrated, in synergy with
IL-23, to drive TH17 cell polarization [10,11]. IL-18 also exerts
multiple effects on NK cells, including increased cytoxicity [12], and
in synergy with IL-2, promotion of NK cell expansion and IFNc
production [13]. Given its widespread immune-augmenting func-
tions, it is not surprising that IL-18 has been evaluated in numerous
animal models of cancer. For example, IL-18 enhances the efficacy
of DNA vaccines directed against prostate-specific antigen [14] or
Fos-related antigen [15]. Additionally, IL-18 augments the efficacy
of DC-based vaccines [16,17] as well as whole-cell tumor vaccines
[18]. However, IL-18 has also been reported to enhance tumor
progression (reviewed in [19]). For example, tumor-produced IL-18
inducesFas ligandexpressioninmelanoma cells,possiblyresulting in
escape from NK cell-mediated immune surveillance [20]. Further-
more, IL-18 has been shown to increase the invasiveness of myeloid
leukemia lines [21].
IL-18 has also been implicated in multiple autoimmune-
associated pathologies (reviewed in [22]). For example, high levels
of IL-18 are found in the synovial fluid of rheumatoid arthritis
patients [23], and alleviation of rheumatoid arthritis symptoms is
associated with a decrease in IL-18 levels [24]. Paradoxically,
given its’ proinflammatory properties, IL-18 is well tolerated and
safe in humans [25]. In contrast, IL-12 is toxic at doses three
orders of magnitude lower [26].
The rationale for the present study was to determine if IL-18
might present a less toxic alternative to IL-12 as an adjunct for
cancer adoptive transfer immunotherapy. In the study described
herein, we demonstrate that IL-18 administration resulted in
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+ human T cells. Concurrently, IL-
18 administration resulted in a decrease in human
CD4
+CD25
+FoxP3
+ regulatory T cells (Tregs). Furthermore, we
find that IL-18 augmented xenogeneic GVHD, and overrode the
suppressive effect of Tregs in vivo. Our findings indicate that by
simultaneously affecting both CD8
+ T cells and Tregs, IL-18 may
alter the set point of an immune response, underscoring the
potential utility of IL-18 as an adjuvant in cancer therapy.
Methods
Mice
All animal experiments were approved by the University of
PennsylvaniaInstitutionalAnimalCareandUseCommittee.NOD/
scid/b2microglobulin
null(NOD/scid/b2m
null)[27]andNOD/scid/IL-
2rc
null (NOG) [28] mice were purchased from the Jackson
Laboratory. Animals were bred in the Animal Services Unit of the
University of Pennsylvania. The mice were housed under specific
pathogen-free conditions in microisolator cages and given unre-
stricted access to autoclaved food and acidified water. Animals of
both sexes were used for experiments at 6–9 weeks of age.
Cells and Animal Injections
Peripheral blood mononuclear cells (PBMCs) were obtained by
leukapheresis of healthy volunteer donors by the University of
Pennsylvania Human Immunology Core. All specimens were
collected under a University Institutional Review Board-approved
protocol, and informed consent was obtained from each donor.
Cells were injected intraperitoneally into non-irradiated host
animals as described in the individual experiments.
Recombinant human IL-18 (SB-485232) and pegylated human
IL-18 (GSK-189720) were prepared as previously described at
GlaxoSmithKline [29]. Subcutaneous injections of 15 mg/animal
were performed daily for the recombinant product and twice
weekly for the pegylated product, taking into consideration the
increased persistence of the pegylated IL-18.
Animal Necropsy
Animals were sacrificed by CO2 asphyxiation. Peripheral blood
was obtained by cardiac puncture, and the spleen, liver, lung, and gut
were isolated and portions were fixed in 4% paraformaldehyde. Liver
leukocytes were separated by Ficoll density gradient centrifugation
and splenocytes were prepared by mechanical disassociation. Cells
were retrieved from the peritoneal cavity by PBS lavage.
Immunohistochemistry
Mouse tissues were fixed in 4% paraformaldehyde and
embedded in paraffin. 5–6 mm sections were cut for immunohis-
tochemical staining. Following deparaffinization and high tem-
perature antigen unmasking procedures, sections were incubated
with murine monoclonal antibodies to human CD25 (Clone 4C9
[Vector], 1:100), or Foxp3 (Clone236A/E7 [AbCam], 1:40).
Sections were then incubated with biotinylated secondary
antibody (goat anti-mouse IgG [Vector]) and signal was localized
using 3,39-diaminobenzidine tetrahydrochloride (DAB, [Vector])
as the chromogen. Hematoxylin was used for counterstaining.
Positively stained cells were quantified with Metamorph software
(Universal Imaging Corporation) using the Manual Count option.
Quantification was performed in a blinded manner. For each
organ, at least 8 fields per animal were tabulated.
Flow cytometry
After euthanasia, peripheral blood, peritoneal cavity washings,
spleen, and liver were obtained from euthanized animals. Single cell
suspensions were stained with conjugated anti-human lymphocyte
surface markers (CD45, clones H130 or 2D1, CD4, clone SK3,
CD8, clone SK1 or 3B5, and CD25, clone M-A251, all from BD
Pharmingen) and Foxp3 (Clone 206D, Biolegend). Cell populations
were analyzed using either LSRII or FACSCalibur flow cytometers
(Becton Dickinson) and Flowjo software (Tree Star). Human
lymphocytes were initially identified by gating on the human
CD45
+ population within the live gate, and human lymphocyte
subsets were further defined within this population. The absolute
number of human cells was determined using TruCount tubes (BD
Biosciences) or a Multisizer 3 (Beckman Coulter).
Adoptive Transfer of Ex Vivo Expanded Tregs
Human CD4
+CD25
high cells were isolated from PBMCs using
magnetic beads (Miltenyi Biotech) as described [30]. Gamma-
irradiated (100 Gy) K562-based antigen presenting cells modified
to express CD64, CD86 and OX40L [31] were used to stimulate
purified populations of CD4
+CD25
high cells, which were expanded
ex vivo in the presence of 300 U/ml IL-2 (Chiron) and 100 ng/ml
Rapamycin (Calbiochem) [30]. After one growth cycle (approx-
imately 14–21 days), the cells were harvested and used for
injection as described in the text.
In Vitro Suppression Assay
Following harvest of expanded T cells (Tregs and control CD4
cells), varying numbers of Tregs were plated in 100 ml of X-VIVO
15+10% human AB serum in round bottom 96 well plates
(Corning Incorporated, Corning, NY). Frozen autologous PBMCs
were thawed, CFSE-labeled, and resuspended in culture medium
at 1610
7/ml. Anti-CD3 beads (Invitrogen) were added at a ratio
of 1 bead per cell. 100 ml of PBMC cell suspension (1610
6 cells)
was added to individual wells in a 96 well plate. CFSE-labeled
PBMCs without CD3 beads (and lacking Tregs) were used as
negative controls; CFSE-labeled PBMC stimulated with anti-CD3
beads (no Tregs) were used as positive controls. Where indicated,
the suppression assay was performed in the presence of 500 ng/ml
recombinant human IL-18. The cultures were harvested four days
later and stained with APC-conjugated anti-CD8 (BD Pharmin-
gen). Data were acquired on a FACSCalibur flow cytometer using
Cell Quest Pro software and analyzed using FlowJo software.
Quantitative analysis of Treg suppression capacity was performed
by gating on CD8
+ CFSE
+ cells [30].
Statistical analysis
All results were expressed as means6standard deviation. Unless
otherwise indicated, the statistical significance of differences
between groups was evaluated by two-sample t tests assuming
equal variance or the Mann-Whitney rank sum test. Survival data
were analyzed by lifetable methods using log rank analysis
performed using SysStat (Systat Software, Inc.).
Results
In preliminary experiments we evaluated recombinant human
IL-18 at doses from 1 to 100 mg/mouse/day for anti-tumor effects
in xenografted mice (data not shown), and 15 mg was chosen as a
daily dose based on tolerability and efficacy, and because this dose
is less than the equivalent maximum tolerated dose that has been
established in monkeys and humans [25,32]. The effects of IL-18
were tested on human T cell subsets using two humanized mouse
models [27,28]. Initially, we determined if IL-18 directly affected
the engraftment of human T cells in NOD/scid/b2m
null mice.
These mice, in addition to lacking mature B and T cells, have
reduced levels of NK cells compared to NOD/scid mice [27].
IL18 Effects on T Cell Subsets
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null mice were injected intraperitoneally with
PBMC, human CD45 positive cells were recovered from
peripheral blood, liver and spleen. Daily subcutaneous injections
of IL-18 caused a substantial increase in the number of human
leukocytes recovered from the blood, liver and spleens of the mice
(Fig. 1A). However, the leukocyte promoting effect of IL-18 was
entirely attributable to increased engraftment of CD8
+ T cells, as
the number of CD4
+ T cells was not increased by IL-18 (Fig. 1B
and 1C). No NK cells or B cells were observed at this time point
(data not shown).
As is shown below, we observed that the IL-18 treated mice
developed xenogeneic GVHD more rapidly than mice engrafted
with PBMC only. We first considered the hypothesis that the IL-18-
mediated increase in human CD8
+ cells could account for this.
However, an alternative hypothesis was also considered, that
decreased engraftment with regulatory T cells could also account
for this, because others have shown that regulatory T cell numbers
and function can influence the onset and severity of xenogeneic
GVHD [33,34]. Although IL-18 did not influence the total number
of CD4 cells (Fig. 1B), there were significant decreases in regulatory
T cells in the IL-18 treated mice, as judged by CD25 and FoxP3
expression (Fig. 2). The percentage and absolute number of
CD4
+CD25
+ cells was decreased in all organs and tissues examined,
i.e. blood, spleen, liver, and peritoneal cavity (Fig. 2A and 2B).
It was possible that the distinct effects of IL-18 on human
lymphocyte subsets were due to relative efficiencies of engraftment
for effector and regulatory subsets in the NOD/scid/b2m
null mice.
To test this possibility, PBMCs were transferred into NOD/scid/
IL-2rc
null (NOG) mice. This strain is highly permissive to human
hematopoietic stem cell engraftment [28]. In NOG mice injected
with PMBC, the mice treated with IL-18 had consistently elevated
numbers of human CD45
+ cells in the peripheral blood, and this
increase was entirely accounted for by increased numbers of CD8
+
cells (Fig. 3A) as was the case for NOD/scid/b2M
null mice. The
NOG mice also had reciprocal decreases in CD4
+CD25
+Foxp3
+
cells in the blood (Fig. 3B) and all tissues examined (data not
shown). The IL-18 mediated decrease in CD4
+CD25
+FoxP3
+ cells
was not due to decreased recovery of the cells, as tissue sections
examined by immunohistochemistry also documented consistent
decreases in cells that stained for Foxp3 (data not shown).
Furthermore, as shown in Fig. 3C, the CD8:Treg ratios in the
peripheral blood of individual animals were markedly increased by
IL-18 treatment.
To assess the effects of IL-18 treatment on human T cell
differentiation in NOG mice after IL-18 treatment, peripheral
blood and spleen were examined by flow cytometry (Fig. 4).
There were only minor effects of IL-18 on the fraction of T cells
with a central memory (CD27
+CD28
+) phenotype, and the modest
effects were different in blood and spleen. There was only a slight
effect of IL-18 on the appearance of T cells with a senescent or
effector memory phenotype (CD28
+CD57
+ or CD27
+CD57
+).
As was mentioned above, we observed that both the NOD/scid/
b2M
null and NOG mouse strains had earlier onset and more severe
xenogeneic GVHD after PBMC engraftment and human IL-18
treatment (Fig. 5). Clinical appearance and examination of weight
curves revealed that IL-18 treated mice had more significant
manifestations of GVHD as indicated by lethargy, hunched
posture, generalized erythema, and a progressive reduction in
mean weights from pretransplant levels (data not shown).
Pathologic examination revealed that the IL-18 treated mice had
more severe tissue infiltration and inflammation of the lung, liver
and gastrointestinal tracts (Supplemental Fig. S1 and S2).
To address the mechanisms for these observations, we used an
adoptive transfer model of effector and regulatory T cells that we
and others have developed [35–38]. PBMCs were subjected to
immunoaffinity bead separation to obtain CD4
+25
high cells and
PBMC depleted of CD4
+25
high cells. The CD4
+25
high cells at
baseline were .70% Foxp3
+, and these cells were expanded using
Figure 1. Human IL-18 Promotes Systemic Increases in Human
CD8 T Cell Numbers in NOD/scid/b2m
null mice injected with
human PBMCs. NOD/scid/b2m
null mice were injected intraperitoneally
with 5610
7 human PBMCs and 24 hours later, a three week course of
daily subcutaneous injections of 15 mg recombinant human IL-18 was
initiated. At the end of the injection time course, the animals were
sacrificed, peripheral blood was collected, and liver and spleen
homogenates were prepared. Human cell populations were detected
by flow cytometry. Absolute cell numbers in the peripheral blood were
determined using Tru-Count tubes; absolute cell numbers from spleen
and liver were determined using a Coulter Multisizer 3. The mean6s.d.
is shown for (A) human CD45
+ cells, (B) human CD4
+ cells, and (C)
human CD8
+ cells. Open bars represent values from mock-treated
animals; filled bars represent values from IL-18 treated animals. These
data are a representative single experiment of seven different
experiments. Asterisks indicate significant differences between mock-
and IL-18-treated animals (n=6 to 10 mice/group; p,0.05).
doi:10.1371/journal.pone.0003289.g001
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of IL-2 and rapamycin as described [37]. NOG mice were injected
with PBMC plus enriched CD4
+CD25
2 effector cells, or with
PBMC plus ex vivo-expanded CD4
+25
+ Tregs. IL-18 treatment in
vivo accelerated GVHD lethality in mice engrafted with PBMC
plus enriched CD4
+CD25
2 effector cells, or with PBMC plus ex
vivo expanded CD4
+25
+ cells (Fig. 6A and B). In contrast, most
mice engrafted with PBMC and ex vivo expanded Tregs had long
term survival. The mice were monitored for engraftment of CD8
+
T cells by periodic measurements of absolute CD8
+ T cell
numbers in peripheral blood using the Trucount assay (Fig. 6C–
E). Mice engrafted with PBMC and CD4
+ effector cells had a
progressive increase in the number of circulating CD8
+ T cells.
Previous studies have shown that human Tregs prevent the
expansion of the presumably xenoreactive CD8
+ T cells in mice
[34]. We found that ex vivo expanded Tregs also prevented the
expansion of CD8
+ T cells in the mice. However, IL-18 treatment
resulted in a striking increase in the numbers of CD8
+ T cells in
mice engrafted with either PBMCs and CD4
+ effectors or with
PBMCs and Tregs. In fact, all IL-18-treated animals were
sacrificed early due to acute GVHD symptoms (Fig. 6E and
data not shown). Thus, in the presence of IL-18, Tregs failed to
control CD8+ T cell proliferation. However, the Kaplan-Meier
curves show a significant difference between each of the 4 groups,
indicating that Tregs have an effect even in the face of IL18
treatment.
Figure 2. Human IL-18 Mediates a Decrease in Tregs in NOD/scid/b2m
null mice Injected with Human PBMCs.5 610
7 PBMCs were
transferred into NOD/scid /b2M
null mice. The day following cell injection, a three week course of subcutaneous huIL-18 injections was initiated.
Animals in the experiment depicted in panel A received twice-weekly doses of 15 mg pegylated human IL-18, while the animals in the experiments
depicted in panel B received daily doses of 15 mg recombinant human IL-18. (A) At the end of IL-18 treatment, cells isolated from the peripheral
blood, peritoneal cavity, spleen and liver were stained with antibodies to human CD45, CD4, and CD25 and analyzed by flow cytometry. The mean
percentage of CD
+CD25
+ cells from each tissue is depicted. Filled bars represent values obtained from IL-18-treated animals; open bars represent
values obtained from mock-treated animals. (B) Paraffin sections from the spleens of mock- or IL-18-treated animals were reacted with antibodies
specific for human CD25 or Foxp3 . Antibody-reactive cells per 400X field were enumerated blindly, and the mean6s.d. depicted. Solid bars depict
sections from IL-18-treated animals, while open bars represent sections from mock-treated animals. The experiment in panel A was performed 2
times, and the experiment in panel B was performed 6 times. Asterisks indicate significant differences between mock- and IL-18-treated animals
(n=8/group; p,0.05).
doi:10.1371/journal.pone.0003289.g002
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Tregs as indicated by the findings of increased CD8
+ T cells in
mice given adoptively transferred Tregs, we next evaluated the
effects of IL-18 on Treg function in vitro. We found that the
addition of IL-18 to culture medium did not affect the population
doubling rate of Tregs in vitro after anti-CD3/CD28 stimulation, in
the presence or absence of IL-2 (data not shown). Furthermore,
IL-18 did not affect the suppressive function of ex vivo expanded
Tregs (Fig. 7) or the expression of Foxp3 (data not shown).
Finally, the upregulation of IL-18Ra did not differ between
CD4
+25
2 or CD4
+25
+ T cells in culture after activation using a
variety of stimulation conditions. However, it is notable that the
expression of IL-18Ra was not sustained on the regulatory T cells
after day 3 in culture, in contrast to bulk CD4 and CD8 T cell
subsets (Fig. 8).
Discussion
This study demonstrates that in immune-deficient mice
engrafted with human PBMCs, human IL-18 administration
exerts opposite effects upon two human cell populations: CD8
+ T
cell numbers are increased, while CD4
+CD25
+FoxP3
+ Treg cell
numbers are markedly decreased. The altered ratio of effector to
Treg engraftment was functionally important as judged by the
accelerated onset and severity of xenogeneic GVHD in the
Figure 3. The Human IL-18-Mediated Decrease in Tregs is Not
Restricted to NOD/scid/b2m
null Mice. NOD/scid/IL-2rc
null (NOG) mice
were injected with 5610
6 human PBMCs, and 24 hours later, a three
week course of daily subcutaneous injections of 15 mg recombinant
human IL-18 was initiated. The absolute numbers of human CD8
+ cells
(A) and CD4
+CD25
+Foxp3
+ cells (B) in the peripheral blood were
determined using TruCount tubes. Values from individual mice are
depicted. (C) The ratio of CD8 cell number to CD4
+25
+Foxp3
+ cell
number for each animal in panels A and B is plotted on a log scale. In
panels A and B, asterisks (*) indicate significant differences between
mock- and IL-18-treated animals (n=6 to 8/group; p,0.05). In panel C,
asterisks (**) indicate p,0.001.
doi:10.1371/journal.pone.0003289.g003
Figure 4. Effects of Human IL-18 on CD8 T Cell Differentiation
in NOG mice. NOG mice were injected intraperitoneally with 5610
6
human PBMCs, and beginning 1 day later, were injected with 15 mg
recombinant human IL-18 daily for three weeks. Spleen tissue and
peripheral blood were collected and analyzed for the presence of
different CD8
+ T cell subsets by flow cytometry. Cell populations were
initially gated on human CD45 and human CD8. Filled bars represent
values mean6s.d. obtained from IL-18-treated animals; open bars
represent values obtained from mock-treated animals. The data in this
figure represent results from one of two independent experiments.
Asterisks indicate significant differences between mock- and IL-18-
treated animals (p,0.05).
doi:10.1371/journal.pone.0003289.g004
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aware of studies with mouse IL-18 that have revealed differential
effects of IL-18 on regulatory and effector T cells [39,40].
Our studies revealed several potential mechanisms for the
effects of IL-18. IL-18 can cause the expansion of mouse NK cells
[13], but has not been reported to directly mediate the expansion
of T cells. Consistent with this, we were unable to demonstrate a
direct effect of IL-18 on the expansion of human effector or
regulatory T cells in vitro. However, we found that the expression of
the IL-18Ra subunit was more prolonged on effector T cells than
Tregs, providing a potential mechanism to explain the reciprocal
effects that we observed in vivo on the effects of IL-18 on effector T
cells and Tregs. There may be important species specific
differences in the biology of IL-18 on human and mouse T cells
[41]. In the mouse, IL-18 has a protective effect on CD4(+)-
mediated acute GVHD [42], and blockade of IL-18 accelerates
acute GVHD-related mortality in mice [43]. Recent studies in the
mouse indicate that IL18 has a role in promoting an IFN-c
dependent positive regulation of memory CD8 T cell proliferation
[44]. Recent studies with human cells indicate that the interaction
of IL-18 treated NK cells and DCs induces maturation of DCs that
subsequently promote Th1 and IFN-c secretion [45]. Together,
the above studies are consistent with our findings, and suggest a
mechanism that IL-18 promotes engraftment of CD8 cells in the
mice at the expense of regulatory T cells, leading to increased
memory CD8 cells and increased xenogeneic GVHD.
A complete mechanistic understanding of the effects mediated
by IL-18 is not yet available from the present findings. It is still not
clear which T cell subsets are preferentially expanded during IL-
18 therapy in the mice, although we found some selective effects
on subsets of CD8 T cells in Figure 4. We do not yet know if CD8
T cells need to be activated in order to be regulated by IL-18.
Similarly, we do not yet know if CD4 T cells need to be present for
the IL-18 effects on CD8 cells. Our data in Figure 6 suggest that
the effects on CD8 T cells and Tregs are independent.
IL-18 has been proposed to have a role in a number of
inflammatory and autoimmune disorders in mice and man [46]. In
mice, IL-18 may have a role in lupus nephritis [47]. In humans,
IL-18 over-expression has been reported in rheumatoid arthritis,
sarcoidosis, adult-onset Still’s disease, vasculitis, lupus, urticaria
and histiocytosis [23,48–54]. Tregs have been reported to be
decreased or to have decreased functional activity in a number of
autoimmune disorders [55], and it is possible that an imbalance of
Tregs and effector T cells due to differential IL-18 signaling
contributes to the loss of tolerance.
Depletion of Tregs in tumor bearing mice enhances the
response to immunotherapy [56]. A high ratio of effector CD8
T cells to Tregs in the tumor microenvironment has been shown to
be a favorable prognostic feature in patients with ovarian cancer
[57,58]. An increase in the ratio of CD8
+ T effector to regulatory
cells in syngeneic mouse tumor models and in humans with cancer
correlates with responses to immunotherapies [59,60]. Thus, the
ability of IL-18 to increase the ratio of effector CD8
+ T cells to
Tregs may have important implications for therapeutic vaccines
and adoptive transfer strategies [61].
The ability of IL-18 to increase the ratio of effector CD8
+ T
cells to Tregs may have important implications for therapeutic
vaccines and cancer therapy. Depletion of Tregs in tumor bearing
mice enhances the response to immunotherapy [56]. A high ratio
of effector CD8 T cells to Tregs in the tumor microenvironment
has been shown to be a favorable prognostic feature in patients
with ovarian cancer [57,58]. Furthermore, an increase in the ratio
of CD8
+ T effector to regulatory cells in syngeneic mouse tumor
models and in humans with cancer correlates with responses to
immunotherapies [59,60].
Our findings may have important implications for cancer
therapy due to the immunosuppressive tumor microenvironment.
Cancer patients have increased tumor infiltrating Tregs [62], and
in many cases, CD8
+ CTLs from the tumor environment are
dysfunctional [63,64]. Recently, it has become more widely
appreciated that successful immunotherapy requires neutralization
of the immunosuppressive features of the tumor microenviron-
ment, in particular Tregs [65]. Thus, by inhibiting Tregs and
promoting conventional T cells, human IL-18 may have potential
to restore immunocompetence in cancer patients, and thereby
augment the effects of cytotoxic and biologic therapies, in order to
provoke and maintain an effective anti-tumor immune response.
Finally, IL-18 may have potential to augment the anti-tumor
effects of donor leukocyte infusions by promoting effector T cells at
the expense of regulatory T cell expansion.
Figure 5. Human IL-18 Accelerates Xenogeneic GVHD in NOG mice. 5610
6 PBMC were transferred into NOG mice on day 0, and IL-18 or PBS
injected daily starting on day 1. On the x-axis are days after transfer of cells. On the y-axis is the proportion of recipients surviving (n=8/group;
P,.02).
doi:10.1371/journal.pone.0003289.g005
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7 Treg-
depleted human PBMCs supplemented with either 4 million autologous CD4
+CD25
2 T cells (‘‘CD4 T cells’’) or 4 million autologous, ex vivo-expanded
CD4
+CD25
+ cells (‘‘Tregs’’). One cohort of each group received daily injections of 15 mg recombinant human IL-18 for three weeks. Human cell
engraftment in the peripheral blood was measured 11, 22, and 30 days post-injection. The animals were followed until the onset of xenogeneic
GVHD. (A) Experimental overview. (B) Kaplan-Meier Survival Analysis (Log-Rank) of the indicated cohorts of mice. The Holm-Sidak method for
multiple comparisons (significance level 0.05) was performed, and showed significant differences between all groups. (C–E) Peripheral blood levels of
human CD8
+ T cells were measured at Day 11 (C), Day 22 (D), and Day 30 (E) post-injection. Note that all IL-18-treated animals are not represented in
panel E due to their death from acute GVHD.
doi:10.1371/journal.pone.0003289.g006
IL18 Effects on T Cell Subsets
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Figure S1 Photomicrographs of lung and liver tissue sections
taken from animals after xenogeneic GVHD induction. 10 million
PBMC were transferred into NOG recipient mice followed by
daily injections of IL-18 (15 mg) or PBS. Animals were euthanized
on day 20 when recipients of PBMC and IL-18 were moribund.
Sections were stained with hematoxylin and eosin. Left: Lung
sections taken from PBMC or PBMC+IL-18 recipients, demon-
strating severe inflammation and lymphocytic infiltration in IL-18
recipients. Right: Liver sections demonstrating marked periportal
lymphocytic infiltrates in IL-18 recipients.
Found at: doi:10.1371/journal.pone.0003289.s001 (5.49 MB TIF)
Figure S2 Photomicrographs of gut tissue sections taken from
animals after xenogeneic GVHD induction. Sections were
obtained from the animals described above in Suppl. Fig. S1.
Left: low magnification. Middle: higher magnification. Right:
highest magnification.
Found at: doi:10.1371/journal.pone.0003289.s002 (5.14 MB TIF)
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Figure 7. Human IL-18 Does Not Prevent Treg Suppressive
Function in Vitro. Purified Tregs were expanded ex vivo for 18 days,
and then tested in an in vitro suppression assay. Autologous PBMCs
were labeled with CFSE and stimulated using anti-CD3 Ab coated beads
and mixed with either no Tregs (top panel) or expanded Tregs at the
indicated ratio (Treg:PBMC) in the presence or absence of recombinant
human IL-18 (500 ng/ml). Histograms show the expansion of CD8
+ cells
on day 4 of culture.
doi:10.1371/journal.pone.0003289.g007
Figure 8. Rapid Down Regulation of IL18-Ra on Tregs Following Cell Activation. Purified populations of Tregs, as well as bulk CD4 and CD8
cells, were activated with either aCD3/aCD28 beads, PHA (5 mg/ml), or PHA+recombinant human IL-18 (500 ng/ml). IL-18Ra expression was
measured by flow cytometry. IL-18Ra MFI on effector CD4 cells (A), Tregs (B) and effector CD8 cells (C) is plotted before stimulation and 1, 2, and 3
days following stimulation.
doi:10.1371/journal.pone.0003289.g008
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